Brief: Icosavax Announces Positive Topline Interim Phase 1 Results For Bivalent VLP Vaccine Candidate IVX-A12

Icosavax

22/05/2023 22:45

May 22 (Reuters) - Icosavax Inc  ICVX.O :
    * ICOSAVAX ANNOUNCES POSITIVE TOPLINE INTERIM PHASE 1
RESULTS FOR
BIVALENT VLP VACCINE CANDIDATE IVX-A12 AGAINST RSV AND HMPV IN
OLDER ADULTS
    * ICOSAVAX INC: IVX-A12 INDUCED ROBUST IMMUNE RESPONSES AT
DAY 28
TO BOTH RSV AND HMPV IN OLDER ADULTS
    * ICOSAVAX INC: IVX-A12 WAS GENERALLY WELL TOLERATED WITH NO
VACCINE-RELATED SAES
    * ICOSAVAX INC: PLANS TO INITIATE A PHASE 2 IMMUNOGENICITY
TRIAL
FOR IVX-A12 IN MID-2023
    * ICOSAVAX INC - CONCURRENT $67.8 MILLION REGISTERED DIRECT
OFFERING; EXTENDS CASH RUNWAY INTO 2H 2025
    * ICOSAVAX INC: NO EVIDENCE OF IMMUNE INTERFERENCE IN STUDY;
INITIAL INDICATION OF COMBINABILITY ACHIEVABLE WITH COMPANY'S
VLP TECHNOLOGY

Source text for Eikon:  ID:nGNX91TmQd 
Further company coverage:  ICVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))